CoChat

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma

Open access
Sadahiro, Hirokazu, Kang, Kyung-Don, Gibson, Justin T., Minata, Mutsuko, Yu, Hai, Shi, Junfeng, Chhipa, Rishi, Chen, Zhihong, Lu, Songjian, Simoni, Yannick, Furuta, Takuya, Sabit, Hemragul, Zhang, Suojun, Bastola, Soniya, Yamaguchi, Shinobu, Alsheikh, Hebaallah, Komarova, Svetlana, Wang, Jun, Kim, Sung-Hak, Hambardzumyan, Dolores, Lu, Xinghua, Newell, Evan W., DasGupta, Biplab, Nakada, Mitsutoshi, Lee, L. James, Nabors, Burt, Norian, Lyse A., Nakano, Ichiro · 2018 · Cancer Research
Cited by 141

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Glioblastoma (GBM) is a lethal disease with no effective therapies available. We previously observed upregulation of the TAM (Tyro-3, Axl, and Mer) receptor tyrosine kinase family member AXL in mesenchymal GBM and showed that knockdown of AXL induced apoptosis of mesenchymal, but not proneural, glioma sphere cultures (GSC). In this study, we report that BGB324, a novel small molecule inhibitor of AXL, prolongs the survival of immunocompromised mice bearing GSC-derived mesenchymal GBM-like tumors. We show that protein S (PROS1), a known ligand of other TAM receptors, was secreted by tumor-associated macrophages/microglia and subsequently physically associated with and activated AXL in mesenchymal GSC. PROS1-driven phosphorylation of AXL (pAXL) induced NFκB activation in mesenchymal GSC, which was inhibited by BGB324 treatment. We also found that treatment of GSC-derived mouse GBM tumors with nivolumab, a blocking antibody against the immune checkpoint protein PD-1, increased intratumoral macrophages/microglia and activation of AXL. Combinatorial therapy with nivolumab plus BGB324 effectively prolonged the survival of mice bearing GBM tumors. Clinically, expression of AXL or PROS1 was associated with poor prognosis for patients with GBM. Our results suggest that the PROS1–AXL pathway regulates intrinsic mesenchymal signaling and the extrinsic immune microenvironment, contributing to the growth of aggressive GBM tumors. Significance: These findings suggest that development of combination treatments of AXL and immune checkpoint inhibitors may provide benefit to patients with GBM. Cancer Res; 78(11); 3002–13. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-2433

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 141

Metadata

Authors
Sadahiro, H., Kang, K.-D., Gibson, J. T., Minata, M., Yu, H., Shi, J., Chhipa, R., Chen, Z., Lu, S., Simoni, Y., Furuta, T., Sabit, H., Zhang, S., Bastola, S., Yamaguchi, S., Alsheikh, H., Komarova, S., Wang, J., Kim, S.-H., Hambardzumyan, D., Lu, X., Newell, E. W., DasGupta, B., Nakada, M., Lee, L. J., Nabors, B., Norian, L. A., & Nakano, I.
Venue
Cancer Research
Published
2018-05-31
Volume
78
Issue
11
Pages
3002-3013
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2793168602
Cited by
141
References
8
FWCI
8.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-2433
The paper
Sadahiro, H., Kang, K.-D., Gibson, J. T., Minata, M., Yu, H., Shi, J., Chhipa, R., Chen, Z., Lu, S., Simoni, Y., Furuta, T., Sabit, H., Zhang, S., Bastola, S., Yamaguchi, S., Alsheikh, H., Komarova, S., Wang, J., Kim, S.-H., . . . Nakano, I. (2018). Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-2433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.